World this year The decline in the commercial capital market is widespread, affecting most local systems, sectors, and phases. If you are building a company in 2022, you should not expect to see the same interest in your project that you may have enjoyed last year. Things have changed.
One of the factors of global market growth at the beginning of this year was the popular reversal. Companies that have fallen into strong demand for COVID-19 and its associated economic impact often see the flag of growth, while companies that have fallen out of profit in the early stages of the disaster are seeing the opposite. In light of this general trend, the Exchange wanted to explore in depth Q1 data over many hot spots last year and early COVID period to see how they hold up today.
The exchange explores startups, markets and currencies.
Read more on TechCrunch + every morning or receive an exchange newsletter every Saturday.
In the tear a several hundred data sets available from CB Insights about investing in global capital in health technology, the word we came up with was retreat. It has not collapsed – deals are still going on in the health technology market – but the market tenant seems to have changed.
We will soon be exploring edtech to see if that sector has met with similar growth in investment needs.
Looking back at TechCrunch’s comparative analysis of CB Insights data, how many deals similar to the last round of $ 5 million raised by telehealth startup in Singapore Folk Normal took place? Let’s find out.
To understand the decline in the health technology market, we will begin with a high-level view, down to two key areas that TechCrunch spoke most about during the epidemic, and then look at will beautify the geographical location of the 2022 medical technology start-up site.
In the first three months of 2022, CB Insights data shows that some $ 10.4 billion was invested in the launch of global health technology. That figure is 36% lower than in Q4 2021, when about $ 16.2 billion was invested worldwide.
Inside this chart is a significant decline of 52% mega-rounds – deals worth $ 100 million or more – from $ 9.2 billion in Q4 2021 to just $ 4.4 billion in Q1. Put in simple English, major medical technical deals have fallen in value by a quarter. Even more so, the Q1 2022 mega-cycle total revenue for health technology was less than a quarter back. until Q2 2020.
Overall the cash flow at the start of medical technology has declined, as well as major checks and major withdrawals. These three factors combine to form part of a regression, although in reality it is a step forward.
What about mental health and telephone health?
In the initial data analysis, the exchange was very interesting in two sub-categories: mental health and telephone health.
Why these two parts? Because many people with a mental health problem were fired during COVID, which led to the need for appliances such as Calm and Headspace, which provide review services. And with the general feeling of non-face-to-face contact that the world has had over the years, seeing doctors and other health professionals has become far more common.
We thought that both sectors – which saw a significant decline in 2020 and 2021 – are likely to endure a significant decline in business volume in the first quarter of the year with a general decline in business activity in the area technology. Are we right? Yes